#1 Clinical Trials Search in Europe

Blu-222

BLU-222 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, focusing on the safety, effectiveness, and potential benefits of BLU-222 in treating various types of cancer, including breast cancer, ovarian cancer, and other solid tumors.

Table of Contents

What is BLU-222?

BLU-222 is a new drug currently being studied for the treatment of various types of advanced solid tumors. It is described as a selective inhibitor of CDK2, which means it targets a specific protein in cancer cells that helps them grow and divide[1]. This drug is taken orally, meaning patients can swallow it as a pill or capsule rather than receiving it through an injection or infusion[1].

What Conditions Does BLU-222 Treat?

BLU-222 is being investigated for several types of advanced solid tumors. The conditions being studied include:

  • Advanced solid tumors: This is a general term for cancers that form solid masses in the body, as opposed to blood cancers[1].
  • HR+ breast cancer: This stands for hormone receptor-positive breast cancer, a type that grows in response to hormones like estrogen or progesterone[1].
  • HER2-negative breast cancer: This is a type of breast cancer that doesn’t have high levels of a protein called HER2 on the surface of the cancer cells[1].
  • Ovarian cancer[1]
  • Endometrial cancer: This is cancer that begins in the lining of the uterus[1].
  • Gastric cancer: Also known as stomach cancer[1].
  • Esophageal adenocarcinoma: This is a type of cancer that starts in the glandular cells of the esophagus, the tube that connects your throat to your stomach[1].
  • Carcinosarcoma: This is a rare type of cancer that contains features of both carcinomas (cancers of epithelial cells) and sarcomas (cancers of connective tissues)[1].

The study is also looking at tumors with a specific genetic feature called CCNE1 amplification. This means that the cancer cells have extra copies of a gene called CCNE1, which may make them more susceptible to treatment with BLU-222[1].

How Does BLU-222 Work?

BLU-222 is a selective inhibitor of CDK2. CDK2 stands for Cyclin-Dependent Kinase 2, which is a protein that plays a crucial role in cell division. By inhibiting CDK2, BLU-222 aims to slow down or stop the growth of cancer cells[1]. This targeted approach is designed to affect cancer cells more than healthy cells, potentially leading to fewer side effects compared to traditional chemotherapy.

The VELA Clinical Trial

BLU-222 is currently being studied in a clinical trial called VELA. This is a Phase 1/2, open-label, first-in-human (FIH) study. Let’s break down what this means:

  • Phase 1/2: This trial combines the initial safety testing of Phase 1 with the early efficacy testing of Phase 2[1].
  • Open-label: This means that both the researchers and the participants know which treatment is being given[1].
  • First-in-human: This is the first time BLU-222 is being tested in people[1].

The study aims to evaluate several aspects of BLU-222:

  • Safety: How well patients tolerate the drug and what side effects it might cause[1].
  • Pharmacokinetics (PK): How the drug moves through the body, including how it’s absorbed, distributed, metabolized, and excreted[1].
  • Pharmacodynamics (PD): How the drug affects the body, including its mechanism of action and relationship between dose and response[1].
  • Anticancer activity: How effective the drug is at fighting cancer[1].

Treatment Arms in the VELA Study

The VELA study is testing BLU-222 in several different ways:

  1. BLU-222 Monotherapy: This arm tests BLU-222 by itself at different doses[1].
  2. BLU-222 + Carboplatin: This arm combines BLU-222 with carboplatin, a commonly used chemotherapy drug[1].
  3. BLU-222 + Ribociclib + Fulvestrant: This arm combines BLU-222 with two other drugs used to treat certain types of breast cancer[1].
  4. BLU-222 + Fulvestrant: This arm tests BLU-222 in combination with fulvestrant alone[1].

These different combinations are being tested to see if BLU-222 works better alone or in combination with other cancer treatments.

What Outcomes Are Being Measured?

The VELA study is measuring several important outcomes to determine how well BLU-222 works and how safe it is. Some of the key outcomes include:

  • Maximum tolerated dose (MTD): This is the highest dose that can be given without causing unacceptable side effects[1].
  • Recommended Phase 2 dose (RP2D): This is the dose that will be used in future larger studies[1].
  • Rate and severity of adverse events: This measures the side effects of the treatment[1].
  • Overall response rate (ORR): This is the percentage of patients whose cancer shrinks or disappears after treatment[1].
  • Duration of Response (DOR): This measures how long the cancer remains decreased or gone after treatment[1].
  • Progression-free survival (PFS): This is the length of time during and after treatment that a patient lives with the disease without it getting worse[1].
  • Overall survival (OS): This measures how long patients live after starting treatment[1].

The study is also measuring various aspects of how the drug behaves in the body, such as how long it stays in the bloodstream and how quickly it’s eliminated[1].

Aspect Details
Drug Name BLU-222
Drug Type Selective inhibitor of CDK2
Administration Oral
Study Phase Phase 1/2
Target Conditions Advanced solid tumors, including HR+ breast cancer, HER2-negative breast cancer, ovarian cancer, endometrial cancer, gastric cancer, esophageal adenocarcinoma, and carcinosarcoma
Study Arms 1. BLU-222 Monotherapy
2. BLU-222 + Carboplatin
3. BLU-222 + Ribociclib + Fulvestrant
4. BLU-222 + Fulvestrant
Primary Outcomes 1. Maximum tolerated dose (MTD)
2. Recommended Phase 2 dose (RP2D)
3. Rate and severity of adverse events
4. Overall response rate (ORR)
Secondary Outcomes Include pharmacokinetic parameters, duration of response, disease control rate, clinical benefit rate, progression-free survival, and overall survival
Study Duration Approximately 43 months

FAQ

  • What is BLU-222? BLU-222 is a selective inhibitor of CDK2, which is being studied as a potential treatment for advanced solid tumors. It is currently in Phase 1/2 clinical trials to evaluate its safety, how it works in the body, and its effectiveness against cancer.
  • What types of cancer is BLU-222 being tested for? BLU-222 is being tested for various types of advanced solid tumors, including HR+ breast cancer, HER2-negative breast cancer, ovarian cancer, endometrial cancer, gastric cancer, esophageal adenocarcinoma, and carcinosarcoma.
  • How is BLU-222 administered? BLU-222 is administered orally, which means it is taken by mouth. The exact dosage is being determined during the clinical trial.
  • Is BLU-222 being tested alone or in combination with other drugs? BLU-222 is being tested both as a single agent (monotherapy) and in combination with other drugs. The combinations being studied include BLU-222 with carboplatin, and BLU-222 with ribociclib and fulvestrant.
  • What are the main goals of the BLU-222 clinical trial? The main goals of the clinical trial are to determine the safe dose of BLU-222, evaluate how well it works against cancer (measured by overall response rate), and assess any side effects. The study also aims to understand how the drug behaves in the body and its effects on certain biomarkers.

Ongoing Clinical Trials on Blu-222

  • Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Italy Spain

Glossary

  • CDK2: CDK2 stands for Cyclin-Dependent Kinase 2. It's a protein that plays a role in cell division and growth. BLU-222 is designed to inhibit this protein, which may help slow down or stop cancer growth.
  • Solid Tumors: Solid tumors are abnormal masses of tissue that don't contain cysts or liquid areas. They may be benign (not cancerous) or malignant (cancerous). Examples include tumors in the breast, lung, or colon.
  • Phase 1/2 Study: This is a type of clinical trial that combines both Phase 1 and Phase 2 studies. Phase 1 focuses on finding a safe dose of a new drug, while Phase 2 starts to test how well the drug works against a specific type of cancer.
  • Pharmacokinetics (PK): This refers to how the body processes a drug. It includes how the drug is absorbed, distributed throughout the body, metabolized (broken down), and excreted.
  • Pharmacodynamics (PD): This refers to how a drug affects the body. It includes the drug's mechanism of action and the relationship between the drug concentration and its effect.
  • HR+ Breast Cancer: HR+ stands for Hormone Receptor Positive. This type of breast cancer has cells with receptors for either estrogen or progesterone, which can promote cancer growth.
  • HER2-negative Breast Cancer: This type of breast cancer does not have high levels of a protein called HER2 (Human Epidermal Growth Factor Receptor 2) on the cell surface.
  • CCNE1 Amplification: This refers to an increase in the number of copies of the CCNE1 gene, which can lead to overproduction of cyclin E1 protein and contribute to cancer growth.
  • Monotherapy: Treatment with a single drug.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing severe side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be safe and effective for further testing in Phase 2 clinical trials.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Biomarkers: Measurable indicators of a biological condition or state, such as a specific molecule in the blood that may indicate the presence or progression of a disease.

References